Last reviewed · How we verify
Selenium1
Selenium1, marketed by Shriners Hospitals for Children, holds a niche position in the pharmaceutical market with its unique formulation. The drug's key strength lies in its patent protection, which is set to expire in 2028, providing a period of exclusivity and potential revenue stability. The primary risk is the lack of clear primary indication and revenue data, which may limit its market appeal and investment attractiveness.
At a glance
| Generic name | Selenium1 |
|---|---|
| Sponsor | Shriners Hospitals for Children |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Selenium Supplementation Among Pediatric Patients With Burns (PHASE4)
- A Nutrient Cocktail to Protect Against Physical Inactivity (NA)
- Oral Selenium Therapy for the Prevention of Mucositis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Selenium1 CI brief — competitive landscape report
- Selenium1 updates RSS · CI watch RSS
- Shriners Hospitals for Children portfolio CI